Many organisations across the pharmaceutical, biotechnology, and medical technology sectors are facing increasing pressure around injectable drug delivery, device supply, time-to-market, and more. Based in Swindon, Quvara Medical is emerging as the CMO partner of choice for companies experiencing such challenges, offering high-quality, regulated, and scalable manufacturing. This is a mission steered by Andy Wertheim, Chief Commercial Officer at Quvara Medical and a seasoned professional being celebrated in the Business Leader Awards 2026. We heard more from Andy below, following his recent success.
“We are focused on solving real market problems rather than simply promoting generic manufacturing capacity.”
In December 2025, Buckland Group completed the acquisition of Becton Dickinson’s (BD) Swindon manufacturing site, a major European high-precision, high-volume medical device production facility. This acquisition has resulted in the creation of Quvara Medical, a brand new entrant built on more than three decades of medical device contract manufacturing.
Since its inception, Quvara Medical has been on a mission to help pharmaceutical, biotechnology, and medical technology companies bring high-quality injectable drug delivery and medical device products to market with confidence, discipline, and scale. Its proposition is built around the meaning behind the Quvara Medical name: Quality, Validation, and Regulatory Approval.
“Quvara Medical is still an emerging brand, but it is built on substantial manufacturing capability, developed over 30+ years with experienced people and a highly relevant industrial base.”
Quvara Medical combines deep manufacturing expertise, established regulated infrastructure, and a commercially responsive approach to building client partnerships. Its specialist capabilities mean that Quvara Medical is particularly well-placed to support organisations requiring credible manufacturing capacity, robust process validation, and a partner that understands the realities of medical device industrialisation.
At its core, Quvara Medical possesses a deep understanding of the unique challenges pharmaceutical, biotechnology, and medical technology clients face as they move from product concept, development, or transfer into robust manufacturing. It specialises in high-volume medical device contract manufacturing, boasting particular strength in injection devices, autoinjectors, pen injectors, syringe-related components, precision moulding, assembly, validation, and regulated manufacturing transfer.
“The values that guide us are quality without compromise, transparency, accountability, technical discipline, and partnership,” Andy told us. “In our sector, excellence is not created by ambition alone; it is created by our people, with evidence, process control, repeatability, and the willingness to solve difficult problems collaboratively with clients.”
As the Chief Commercial Officer of Quvara Medical, Andy Wertheim is responsible for leading the commercial transformation of the business, converting proven manufacturing capability into a scalable, market-facing growth platform with board-level accountability. Andy is a collaborative C-Suite leader who boasts extensive experience in strategic business management and performance growth across multiple industries and business areas.
Andy’s professional career has been shaped by a consistent interest in how organisations create value: commercially, operationally, strategically, and culturally. He has spent much of his career working at the intersection of commercial growth, portfolio strategy, organisational development, and regulated healthcare markets.
“What initially motivated me was the opportunity to work in a sector where business performance and human impact are directly connected,” he shared. “Medical technology is commercially demanding, but it also matters. The products and services we support ultimately contribute to patient care, healthcare efficiency, and improved access to treatment.”
“Medical technology is commercially demanding, but it also matters. The products and services we support ultimately contribute to patient care, healthcare efficiency, and improved access to treatment.”
Over time, Andy became increasingly interested in the broader mechanics of value creation. He was fascinated by the ways in which businesses identify opportunity, convert capability into market relevance, build trusted customer relationships, and create sustainable growth. This perspective has led him into leadership roles where the task was not simply to sell, but to shape direction, build confidence, and align teams behind a clear commercial and strategic agenda.
Andy’s philosophy as a business leader is centred on creating clarity, confidence, and momentum within his team. He understands that it is important to set direction, but even more important to make that direction meaningful to the people who deliver it. This understanding sees the CCO translating strategy into practical priorities, ensuring that his teams understand why their work matters and creating an environment where high standards are expected and supported.
Ultimately, Andy believes that successful leadership combines ambition with realism. It is essential to have a bold view of what a business can become, but Andy asserts that ambition must be grounded in evidence, disciplined execution, and honest assessment of risk. In regulated medical technology, credibility is crucial; clients, colleagues, and investors must feel assured that commitments are considered, achievable, and supported by the right capability.
“I also believe leadership is a service role,” he added. “The leader’s job is to add value to the people and organisations around them, remove barriers, make good decisions, and help others perform at their best. Sustainable success comes when commercial ambition, operational discipline, and organisational culture are aligned.”
This approach – combining commercial ambition, operational discipline, and organisational culture – is precisely how Andy intends to lead Quvara Medical forward. Over the next five years, the company intends to differentiate itself through a more focused, commercially agile, and partnership-led approach to regulated medical device contract manufacturing, especially as the landscape continues to undergo significant evolution.
The injectable drug delivery market is changing rapidly. Growth in biologics, GLP-1 therapies, self-administration, drug-device combination products, and patient-centric delivery formats is placing new pressure on manufacturing capacity, device platforms, and industrialisation pathways. Innovation in this environment is not only about inventing and industrialising new devices, but also about helping clients scale safety, validate robustly, transfer effectively, and bring products to market with less friction.
Moving forward, Andy and his team strive to ease the industry’s pain points and tackle these challenges head-on. “Our goal is to build Quvara Medical into a trusted manufacturing partner for pharmaceutical, biotechnology, and medtech organisations requiring high-quality device manufacturing support,” he told us. “We want to be recognised for technical discipline, responsive partnership, and the ability to help clients bridge the gap between product ambition and industrial reality.”
He continued: “We are also focused on creating a scalable commercial platform: one that can support existing device categories, adjacent injectable and syringe-related opportunities, and future growth areas where manufacturing excellence and regulatory confidence are decisive.”
Since its creation in 2025, Andy has helped position Quvara Medical as a credible new partner for pharmaceutical, biotechnology, and medical technology organisations, building on an established base of 65+ inherited client relationships, many supported by prior site audits. The Chief Commercial Officer has demonstrated the importance of aligning strategy, capability, and culture across organisations, showcasing how a team operating with a shared vision can achieve sustained success.
For his exceptional leadership capabilities and significant contributions to the medical technology field, Andy Wertheim has been deservingly recognised as the UK’s Most Strategic MedTech Commercial Leader 2026.
To aspiring business leaders who hope to follow in these ambitious footsteps, Andy advised: “My advice would be to become fluent in both strategy and delivery but always centred on people. People are the key. Many talk about growth, transformation, or opportunity. Fewer can turn these ideas into practical action, measurable progress, and organisational confidence. The strongest leaders connect the big picture with the operational detail.”
Contact Details
Contact: Andy Wertheim
Company: Quvara Medical Ltd
Web Address: www.quvaramedical.com
